Capricor Therapeutics
CAPR
#5206
Rank
ยฃ1.20 B
Marketcap
ยฃ20.89
Share price
-2.69%
Change (1 day)
169.08%
Change (1 year)

Revenue for Capricor Therapeutics (CAPR)

Revenue in 2025 (TTM): N/A

a decrease over the revenue in the year 2024 that were of ยฃ17.74 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Capricor Therapeutics from 2009 to 2025

Annual revenue

Year Revenue Change
2025 N/A-100%
2024 ยฃ17.74 M-10.2%
2023 ยฃ19.76 M837.08%
2022 ยฃ2.1 M1062.45%
2021 ยฃ0.18 M-20.29%
2020 ยฃ0.22 M-70.3%
2019 ยฃ0.76 M-41.79%
2018 ยฃ1.31 M-18.76%
2017 ยฃ1.62 M-37.31%
2016 ยฃ2.58 M1.46%
2015 ยฃ2.54 M-4.79%
2014 ยฃ2.67 M
2013 N/A-100%
2012 ยฃ0.12 M-86.12%
2011 ยฃ0.87 M
2010 N/A
2009 N/A

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Johnson & Johnson
JNJ
ยฃ71.83 BN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
ยฃ2.31 BN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Cytokinetics
CYTK
ยฃ78.88 MN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Celldex Therapeutics
CLDX
ยฃ1.15 MN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
ยฃ6.59 MN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Eterna Therapeutics
ERNA
ยฃ0 MN/A๐Ÿ‡บ๐Ÿ‡ธ USA